Sign in

You're signed outSign in or to get full access.

M

MOSAIC (MOS)·Q4 2025 Earnings Summary

Mosaic Posts Q4 Loss on Notable Items; Full Year EBITDA Tops $2.4B

February 24, 2026 · by Fintool AI Agent

Banner

Mosaic Company (NYSE: MOS) reported Q4 2025 results that missed consensus expectations across key metrics, with revenue of $2.97B falling 15.8% below the $3.53B estimate and a net loss of $519M driven by $414M in notable items . Despite the weak quarter, full year 2025 performance was solid with adjusted EBITDA of $2.42B and net income of $541M . The stock closed at $28.49 on February 24, with earnings released after market close.

Did Mosaic Beat Earnings?

No. Mosaic missed on all key metrics in Q4 2025:

MetricQ4 2025 ActualConsensusSurprise
Revenue$2,974M $3,530M*-15.8%
Adjusted EBITDA$505M $769M*-34.3%
Net Income($519M) Positive expectedLarge miss
Operating Earnings($101M) Positive expectedMiss

*Values retrieved from S&P Global

The quarterly loss was driven by $414M in notable items that impacted results, including write-downs and charges . On an adjusted basis, Q4 EBITDA of $505M was below expectations but represented the impact of soft U.S. demand in phosphates and challenging market conditions in Brazil.

Full Year 2025 Performance

The full year tells a better story:

MetricFY 2025FY 2024Change
Revenue$12,052M ~$11,100M+9%
Adjusted EBITDA$2,421M ~$2,200M+10%
Net Income$541M ~$175M+209%
Operating Earnings$822M ~$430M+91%
FintoolAsk Fintool AI Agent

How Did Each Segment Perform?

Segment Breakdown

Phosphate: Soft Q4 Demand, But Production Improving

MetricQ4 2025FY 2025
Net Revenues$1,015M $4,577M
Operating Earnings (Loss)($98M) $135M
Adjusted EBITDA$144M $917M
Sales Volumes1.3MT 5.9MT
Production Volumes1.7MT 6.3MT
DAP FOB Plant$686/t $670/t
Cash Cost of Conversion$112/t $125/t

Key takeaways:

  • Q4 sales volumes of 1.3MT were impacted by soft U.S. demand; management expects recovery to 1.7-1.9MT in Q1 2026
  • Cash cost of conversion improved to $112/t, down 16% from the high-water mark earlier in 2025
  • North America phosphoric acid production trending higher — Q4 2025 at 770K MT vs 635K MT in Q4 2024
  • Near-record phosphate rock production of 14.6MT for FY 2025

Potash: Record International Performance

MetricQ4 2025FY 2025
Net Revenues$686M $2,662M
Operating Earnings$58M $638M
Adjusted EBITDA$336M $1,183M
Sales Volumes2.2MT 9.0MT
Production Volumes2.2MT 8.8MT
MOP FOB Mine$264/t $255/t
Cash Cost of Production$77/t $75/t

Key takeaways:

  • Record international sales volumes of 5.5MT for full year, contributing to strong results
  • Highest MOP production in 8 years despite lower-than-expected Q4 volumes
  • Signed Carlsbad sale agreement with ~$30M expected value and ~$20M ARO reduction

Mosaic Fertilizantes: Challenging Q4, Strong Full Year

MetricQ4 2025FY 2025
Net Revenues$1,146M $4,847M
Operating Earnings (Loss)($26M) $277M
Adjusted EBITDA$45M $567M
Sales Volumes2.1MT 9.0MT

Key takeaways:

  • Q4 results negatively impacted by credit challenges, intensified competition, and rapid rise in sulfur prices
  • Full year Adjusted EBITDA of $567M was up 65% YoY, the third highest in operating history
  • Cost management focus yielded blended rock costs of $97/t in 2025, lowest since 2021

How Did the Stock React?

Earnings were released after market close on February 24, 2026. The stock closed at $28.49 (-1.69% on the day). Key context:

MetricValue
Current Price$28.49
52-Week High$38.23
52-Week Low$22.36
Analyst Target Price$32.27*
Implied Upside+13.3%
Market Cap$9.04B

*Values retrieved from S&P Global

The stock has rallied from the November 2025 lows near $23 but remains 25% below the 52-week high. The analyst target price of $32.27 implies 13% upside from current levels.

FintoolAsk Fintool AI Agent

What Did Management Guide?

Q1 2026 Outlook

SegmentMetricQ1 2026 Guidance
PhosphateSales Volumes1.7-1.9 MT
PhosphateDAP Prices (FOB Plant)$640-$670/t
PotashSales Volumes2.0-2.2 MT
PotashMOP Prices (FOB Mine)$255-$275/t

Full Year 2026 Guidance

Metric2026 Guidance
Phosphate ProductionAt or above 7.0 MT
Potash Production~9 MT
Capital Expenditures~$1.5B
D&A$1.1-$1.2B
SG&A$530-$550M
Net Interest Expense$200-$220M
Adjusted Effective Tax RateLow-mid 30s%

Pricing Sensitivities

Management provided helpful sensitivities for modeling :

  • DAP: $10/t price change = $80M Adjusted EBITDA impact
  • MOP: $10/t price change = $65M Adjusted EBITDA impact

What Changed From Last Quarter?

Negative developments:

  1. Revenue declined significantly — Q4 at $2.97B vs Q3 at $3.45B (-14%)
  2. Notable items of $414M created a large quarterly loss
  3. Working capital increased by $1.0B due to inventory build
  4. Free cash flow was negative at ($535M) for full year 2025
  5. Debt increased — higher working capital needs drove borrowing

Positive developments:

  1. Phosphate production improving — Q4 at 1.7MT with momentum continuing into 2026
  2. Cost reductions achieved — $150M value capture target met in 2025, additional $100M targeted for 2026
  3. Record potash international sales — 5.5MT for the full year
  4. Mosaic Biosciences growing — Positively contributed to Q4 EBITDA, net sales expected to double in 2026

Capital Allocation and Balance Sheet

Cash Flow and Leverage

MetricQ4 2025FY 2025
Operating Cash Flow (before working capital)$306M $1,786M
Working Capital Change($362M) ($961M)
Net Operating Cash Flow($56M) $825M
Capital Expenditures($350M) ($1,359M)
Free Cash Flow($406M) ($535M)
Dividends$70M $280M

2026 Priorities

Management outlined capital priorities for 2026 :

  1. Regular dividend — maintaining $280M annual pace
  2. Debt paydown — top priority after working capital normalizes

Working Capital Build

The $1.0B increase in working capital was driven by inventory :

  • Raw materials up $346M from higher sulfur prices and elevated rock inventories
  • Finished goods up $428M from price increases and inventory build in North America and Brazil
  • Management expects rock inventories to decrease as phosphate production continues improving
  • Finished goods to reverse over the next few quarters

Strategic Updates

Asset Monetization Progress

AssetStatusExpected Value
Ma'aden stake~111M shares with clear monetization path~$1.8B (up ~20% in 2025)
Patos de MinasClosed in 2025~$111M
TaquariClosed in 2025~$27M + ~$22M ARO reduction
CarlsbadSale agreement signed in 2025~$30M + ~$20M ARO reduction
Araxa/PatrocinioNiobium opportunity advancing in 2026TBD
Land monetizationSeveral deals expected in 2026TBD

Value Capture Initiative

Having achieved the $150M cost reduction target in 2025, Mosaic is targeting an additional $100M in 2026 through :

  • Further cost reductions with focus on North America operations
  • Supply chain efficiencies — optimizing excess inventories, scrap, demurrage
  • Improved pricing, netbacks, and margin optimization
  • Contract management using AI to prevent "over-invoicing"
  • Shared services transformation
  • Further reduction in administrative functions

Mosaic Biosciences Growth

The biologicals and micronutrients business achieved several milestones :

  • Positively contributed to Q4 Adjusted EBITDA
  • Successfully launched 5 new products in 2025
  • Expanded to 16 countries with 60+ registrations
  • Net sales targeted to double again in 2026

Market Outlook

Phosphate Market

  • Global demand still constrained by supply; Chinese export policy could further trim supply
  • DAP affordability improved in Q4, with prices increasing as seasonal demand builds
  • Stripping margins at five-year lows on higher raw material prices, pressuring producer economics

Potash Market

  • Affordability driving demand growth with largely balanced supply/demand supporting stable prices
  • Low Brazil and China inventory levels (stocks-to-use at 15-16%) support 2026 demand

Agricultural Fundamentals

  • Crop prices remain range-bound at levels supportive of fertilizer demand
  • Brazil planted area expanding (93.8M Ha in 25/26, 95.9M Ha expected in 26/27), requiring fertilizer to drive yield increases
FintoolAsk Fintool AI Agent

Forward Catalysts

Near-term (Q1-Q2 2026):

  • Q1 2026 volume recovery in Phosphate (guided 1.7-1.9MT vs 1.3MT in Q4)
  • Working capital release as inventories normalize
  • Additional asset monetization deals expected

Medium-term (2026):

  • Phosphate production target of 7.0+ MT (highest in recent years)
  • $100M additional value capture from cost initiatives
  • Mosaic Biosciences sales doubling
  • Niobium opportunity at Araxa/Patrocinio advancing

Risks to watch:

  • Chinese phosphate export policy (additional restrictions could further tighten supply)
  • Raw material cost volatility (sulfur, ammonia)
  • Brazil credit conditions and agricultural market health
  • Working capital management and debt levels

Data sourced from Mosaic Company Q4 2025 earnings materials released February 24, 2026. Consensus estimates from S&P Global.

Related Links: